Brussels, 28 May (LaPresse) – The first doses of an experimental antiviral drug for the treatment of hantavirus are being shipped to France, Spain and the Netherlands for the treatment of patients or for the conduct of clinical trials. The European Commission reports this, noting that although there are currently no approved drugs or vaccines for the treatment or prevention of hantavirus, the European Medicines Agency (EMA) has identified favipiravir as the most promising candidate for use in clinical trials or compassionate use protocols. It is specified that the decision on its use will be a matter for the Member States concerned. The 1,400 favipiravir tablets have been made available to EU Member States thanks to a donation from Fujifilm Pharmaceuticals in Japan and the strong cooperation between the EU and Japan on health emergency preparedness and response. The donation was facilitated by the Japanese authorities and the European Union Delegation to Japan.
Hantavirus: experimental antiviral doses sent to France, Spain and the Netherlands
Brussels, 28 May (LaPresse) – The first doses of an experimental antiviral drug for the treatment of hantavirus are being shipped to France, Spain and the Netherlands for the treatment of patients or for the conduct of clinical trials. The European Commission reports this, noting that although there are currently no approved drugs or vaccines for the treatment or prevention of hantavirus, the European Medicines Agency (EMA) has identified favipiravir as the most promising candidate for use in clinical trials or compassionate use protocols. It is specified that the decision on its use will be a matter for the Member States concerned. The 1,400 favipiravir tablets have been made available to EU Member States thanks to a donation from Fujifilm Pharmaceuticals in Japan and the strong cooperation between the EU and Japan on health emergency preparedness and response. The donation was facilitated by the Japanese authorities and the European Union Delegation to Japan.
